Plexitome, a new device for anterior stromal puncture (ASP), is now available through a strategic partnership between Plexitome Medical and VEO Ophthalmics. The device can be used for treatment of recurrent corneal erosion (RCE) and other epithelial basement membrane dystrophies (EBMD), Plexitome Medical said in a press release. 

The Plexitome device features a 6.2 mm diameter disc array with approximately 675 precisely engineered microspikes, delivering controlled and uniform puncture depth through Bowman's layer of the cornea without creating optically evident anterior stromal scarring. With up to 3,375 individual epithelial attachment points created over 5 imprints, the device enhances corneal healing and reduces long-term recurrence rates, the company claims. According to Plexitome Medical, in clinical use, Plexitome has demonstrated the ability to penetrate Bowman's layer through both debrided and loose, intact epithelium, creating stable epithelial attachments. It may also shorten healing times for large corneal abrasions and help mitigate the risk of recurrence in erosive conditions. 

VEO Ophthalmics will lead the commercial rollout of Plexitome, providing access, training and support to corneal specialists and surgical teams across the United States, and globally.